JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB211156

Phagocytosis Assay Kit (Zymosan, Colorimetric)

Be the first to review this product! Submit a review

|

(8 Publications)

Phagocytosis Assay Kit ab211156 uses a Zymosan substrate to provide a robust system for screening TLR ligands, phagocytosis activators or inhibitors.
2 Images
Functional Studies - Phagocytosis Assay Kit (Zymosan, Colorimetric) (AB211156)
  • FuncS

Supplier Data

Functional Studies - Phagocytosis Assay Kit (Zymosan, Colorimetric) (AB211156)

Zymosan Particles Engulfment by Raw 264.7 Macrophage

Functional Studies - Phagocytosis Assay Kit (Zymosan, Colorimetric) (AB211156)
  • FuncS

Supplier Data

Functional Studies - Phagocytosis Assay Kit (Zymosan, Colorimetric) (AB211156)

Inhibition of Raw 264.7 Macrophage Phagocytosis by Cytochalasin D.

50,000 cells/well of Raw 264.7 macrophages were seeded overnight in a 96-well plate. Cytochalasin D was used to pretreat Raw 264.7 cells for 1 hr at 37°C before addition of Zymosan at a ratio of 50 : 1 Zymosan particles per cell. Phagocytosis was stopped after 30 minutes and the amount of engulfed Zymosan particles was determined as described in the Assay Protocol.

Key facts

Detection method

Colorimetric

Sample types

Adherent cells

Assay type

Cell-based

Assay Platform

Microplate reader

Product details

Phagocytosis Assay Kit ab211156 uses a Zymosan substrate to provide a robust system for screening TLR ligands, phagocytosis activators or inhibitors.

Colorimetric phagocytosis assay principle
The phagocytosis assay uses pre-labeled Zymosan particles as a pathogen to trigger phagocytosis. The label on the engulfed Zymosan particles then reacts with a substrate to produce a colorimetric signal that can be detected by absorbance at 405 nm.
External particles are blocked before the reaction with a blocking reagent, ensuring the signal is directly proportional to the amount of internalized particles.

This format provides a quantitative, high-throughput method to accurately measure phagocytosis, and avoids subjective manual counting of Zymosan particles inside cells.

Phagocytosis assay protocol summary
- add Zymosan substrate to cell cultures and incubate for 15 min to 2 hrs
- remove culture medium, and wash cells
- add fixation solution and incubate for 5 min and then wash cells
- add blocking reagent and incubate for 60 min and then wash cells
- add permeabilization solution and incubate for 5 min and then wash cells
- add detection reagent and incubate for 60 min and then wash cells
- add detection buffer and incubate for 10 min
- add substrate and incubate for 5-20 min
- add stop solution and analyze with plate reader

Getting the best performance from ab211156
This kit is suitable for adherent phagocytes only.

Each 20 test kit provides sufficient quantities to perform 20, 10 or 5 tests in a 96-,48- or 24-well plate respectively. Each 96 tests kit provides sufficient quantities to perform 96, 48 or 24 tests in a 96-, 48- or 24-well plate respectively. Each 5 x 96 tests kit provides sufficient quantities to perform 5 x 96, 48 or 24 tests in a 96-, 48- or 24-well plate respectively.

Related phagocytosis assays
Phagocytosis Assay Kit (Green E.coli) ab235900
Phagocytosis Assay Kit (Red E. coli) ab235901
Phagocytosis Assay Kit (Green Zymosan) ab234053
Phagocytosis Assay Kit (Red Zymosan) ab234054

Other notes
In mammals, phagocytosis by phagocytes (e.g., macrophages, dendritic cells, and neutrophils) is essential for a variety of biological events. Phagocytosis comprises a series of events, starting with the binding and recognition of particles by cell surface receptors, followed by the formation of actin-rich membrane extensions around the particle.

Zymosan (Saccharomyces cerevisiae) is prepared from yeast cell wall and consists of protein-carbohydrate complexes. Zymosan is a commonly used pathogen in phagocytosis assays.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

What's included?

{ "values": { "1x96Tests": { "sellingSize": "1 x 96 Tests", "publicAssetCode":"ab211156-1x96Tests", "assetComponentDetails": [ { "size":"1 x 20 mL", "name":"Fixation Solution", "number":"AB211156-CMP05", "productcode":"" }, { "size":"1 x 20 µL", "name":"Phagocytosis Inhibitor", "number":"AB211156-CMP06", "productcode":"" }, { "size":"1 x 12 mL", "name":"Substrate", "number":"AB211156-CMP08", "productcode":"" }, { "size":"1 x 50 µL", "name":"250X Detection Reagent", "number":"AB211156-CMP02", "productcode":"" }, { "size":"1 x 10 mL", "name":"Detection Buffer", "number":"AB211156-CMP04", "productcode":"" }, { "size":"1 x 1 mL", "name":"Zymosan Suspension", "number":"AB211156-CMP09", "productcode":"" }, { "size":"1 x 12 mL", "name":"Stop Solution", "number":"AB211156-CMP07", "productcode":"" }, { "size":"1 x 200 µL", "name":"Blocking Reagent", "number":"AB211156-CMP03", "productcode":"" }, { "size":"1 x 1.5 mL", "name":"10X Permeabilization Solution", "number":"AB211156-CMP01", "productcode":"" } ] } } }

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
+4°C

Product protocols

Target data

Publications (8)

Recent publications for all applications. Explore the full list and refine your search

Journal of inflammation research 17:8085-8098 PubMed39507267

2024

Combination of Methotrexate and Resveratrol Reduces Pro-Inflammatory Chemokines in Human THP-1 Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Moonerah M Al-Nasser,Mashael J Al-Saeedi,Saltana A Alhowaiti,Zakia Shinwari,Fatimah S Alhamlan,Hani Alothaid,Saad Alkahtani,Ahmed A Al-Qahtani

Life science alliance 7: PubMed39025525

2024

C/EBPβ deletion in macrophages impairs mammary gland alveolar budding during the estrous cycle.

Applications

Unspecified application

Species

Unspecified reactive species

Michelle D Rojo,Ishitri Bandyopadhyay,Caitlin M Burke,Alexa D Sturtz,Emily S Phillips,Megan G Matherne,Samuel J Embrey,Rebecca LaRue,Yinjie Qiu,Kathryn L Schwertfeger,Heather L Machado

Frontiers in immunology 14:1165602 PubMed37077909

2023

Loss of NLRP3 reduces oxidative stress and polarizes intratumor macrophages to attenuate immune attack on endometrial cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaolu Zhu,Yanli Xu,Juan Wang,Zhuowei Xue,Tian Qiu,Jing Chen

Frontiers in immunology 13:1064303 PubMed36505450

2022

Persistent expression of NLRP3 in spinal microglia promotes development of lumbar disc degeneration.

Applications

Unspecified application

Species

Unspecified reactive species

Peng Wang,Jing Zhang

Frontiers in immunology 13:1057746 PubMed36405726

2022

NLRP3+ macrophages aggravate inflammatory cystitis in diabetes.

Applications

Unspecified application

Species

Unspecified reactive species

Yubing Peng,Yan Gao

Frontiers in immunology 13:1008727 PubMed36189317

2022

Clec7a expression in inflammatory macrophages orchestrates progression of acute kidney injury.

Applications

Unspecified application

Species

Unspecified reactive species

Yaqiong Wang,Xianzhe Li,Xialian Xu,Jinbo Yu,Xiaohong Chen,Xuesen Cao,Jianzhou Zou,Bo Shen,Xiaoqiang Ding

Clinical and translational medicine 12:e931 PubMed35842904

2022

ISG15 deficiency features a complex cellular phenotype that responds to treatment with itaconate and derivatives.

Applications

Unspecified application

Species

Unspecified reactive species

Syed Fakhar-Ul-Hassnain Waqas,Aaqib Sohail,Ariane Hai Ha Nguyen,Abdulai Usman,Tobias Ludwig,Andre Wegner,Muhammad Nasir Hayat Malik,Sven Schuchardt,Robert Geffers,Moritz Winterhoff,Sylvia Merkert,Ulrich Martin,Ruth Olmer,Nico Lachmann,Frank Pessler

Journal of lipid research 62:100108 PubMed34418413

2021

Distinct biological activities of isomers from several families of branched fatty acid esters of hydroxy fatty acids (FAHFAs).

Applications

Unspecified application

Species

Unspecified reactive species

Pratik Aryal,Ismail Syed,Jennifer Lee,Rucha Patel,Andrew T Nelson,Dionicio Siegel,Alan Saghatelian,Barbara B Kahn
View all publications
websiteProtocolBooklet
en

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com